On Dec 18, 2019, the UK National Institute for Health and Care Excellence (NICE) published recommending cannabidiol with clobazam as an option for treating seizures associated with Dravet syndrome or Lennox-Gastaut syndrome. The guidance states that the frequency of convulsive (Dravet) or drop (Lennox-Gastaut) seizures should be checked every 6 months, and that cannabidiol should be stopped if the frequency has not fallen by at least 30% compared with the 6 months before starting treatment. This guidance applies only if the company provides cannabidiol with the discount specified in the commercial arrangement.

中文翻译：

---

卡那比二醇和氯巴沙姆用于与Dravet和Lennox-Gastaut综合征相关的癫痫发作。

2019年12月18日，英国国家健康与护理卓越研究所（NICE）发布了推荐使用大麻双酚和氯巴沙姆作为治疗与Dravet综合征或Lennox-Gastaut综合征相关的癫痫发作的选择。指南指出，应每6个月检查一次惊厥性（Dravet）或掉落性（Lennox-Gastaut）癫痫发作的频率，如果与开始前的6个月相比发作频率未下降至少30％，则应停止大麻酚治疗。本指南仅在公司为大麻二酚提供商业安排中指定的折扣时适用。